The New England Journal of Medicine (NEJM Group) has published positive Phase 3 results regarding our medicine in children aged 1 to 11 years with eosinophilic esophagitis (#EoE). Read more about how we are working with Regeneron to change the standard of care for young children living with the disease. Read our press release: http://spkl.io/604447BBQ
Fantastic news, Sanofi! 🎉 The positive Phase 3 results published by The New England Journal of Medicine regarding your medicine for children aged 1 to 11 with eosinophilic esophagitis (#EoE) are truly promising. It's exciting to see your collaboration with Regeneron potentially changing the standard of care for young patients facing this challenging condition. #Sanofi #Regeneron #EoE #MedicalResearch #Phase3Results #PediatricHealth
Congrats, Sanoif!
Ohh, that awesome! Well if you need an experienced pediatric representative who has great relationships with the pediatricians in the East Texas area, in pediatric pharmaceutical and healthcare services. I’m your guy.
So wonderful to see this ….
Exciting news! Congratulations on the positive Phase 3 results for your medicine in children with eosinophilic esophagitis. Your collaboration with Regeneron is paving the way for better standards of care for young patients battling this disease.
Great news from medical research! The positive Phase 3 results are a breakthrough for children with eosinophilic esophagitis. Our partnership with Regeneron will revolutionize the standard of care. A significant step forward for young patients.
Congratulations
Fantastic news! 🌟 Excited to see positive impacts for young patients! #EoE
Inspiring!
This is a significant step forward in improving the lives of young children with eosinophilic esophagitis.��